Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs) subject to priority review under section 505(j)(11) of the Federal Food, Drug, and Cosmetic (FD&C) Act and certain ANDAs with a competitive generic therapy designation under section 506H of the FD&C Act. The tables below provide data on the total number of ANDAs in these two categories that are either awaiting FDA action or awaiting applicant action at the end of each reporting quarter, as well as the number of ANDAs approved in each of these categories during the reporting quarter. The numbers reported below only reflect ANDAs that have been received for review pursuant to section 505(j) of the FD&C Act; if a new ANDA submission has not yet been received for review at the end of the reporting quarter, meaning FDA has not yet made a threshold determination whether the submission is substantially complete, it will be reported in the next quarter after it is received for review.

Section 805 of FDARA requires FDA to include in the reports under section 807 an annual report on the number of pending petitions under section 505(j)(2)(c) of the FD&C Act (commonly referred to as suitability petitions) and the number of such petitions pending a substantive response for more than 180 days from the date of receipt. This information is provided by fiscal year in the last table below.

Reports available:

• FY 2023 ANDAs Subject to Priority Review under Section 505(j)(11) of the FD&C Act
• FY 2023 ANDAs with a Competitive Generic Therapy Designation under Section 506H of the FD&C Act
• FY 2023 ANDAs with a Competitive Generic Therapy Designation under Section 506H of the FD&C Act for which the Secretary has taken action pursuant to Section 506H (c)
• FY 2023 Pending Suitability Petitions under Section 505(j)(2) (c) of the FD&C Act
• Previous Activities Reports
• Additional data on the activities of FDA’s Office of Generic Drugs is available here.

NOTE: Numbers reflect current data at the time of posting and may change based on refreshed counts in our tracking systems.

FY 2023 ANDAs Subject to Priority Review under Section 505(j)(11)* of the FD&C Act

*The counts in this table include ANDAs that were subject to priority review under subparagraphs (A) and (D) of section 505(j)(11) of the FD&C Act, as added by section 801 of the Food and Drug Administration Reauthorization Act of 2017 (FDARA).

FY 2023 ANDAs with a Competitive Generic Therapy Designation under Section 506H of the FD&C Act

FY 2023 ANDAs with a Competitive Generic Therapy Designation under Section 506H of the FD&C Act for which the Secretary has taken action pursuant to Section 506H(c)

FY 2023 Pending Suitability Petitions under Section 505(j)(2) (C) of the FD&C Act⁺

⁺These numbers are reported annually and will be posted when available.

Previous Activities Reports

• Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2022)
• Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2021)
• Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2020)
• Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2019)
• Activities Reports of the Generic Drugs Program - FDARA Title VIII Sections 807 and 805 (FY 2018)